The NAST system is a cutting-edge in-house antibiotic susceptibility testing (AST) solution designed to empower veterinarians and animal clinics with rapid, accurate, and cost-effective antimicrobial resistance diagnostics. It utilizes patented microfluidic technology and an automated detection instrument to generate Minimum Inhibitory Concentration (MIC) values and categorize antimicrobial susceptibility much faster than traditional laboratory methods — significantly reducing turnaround time from days to as little as 6–32 hours.
AST reports available in 6–32 hours, enabling timely treatment decisions.
Leveraging microfluidic technology for precise susceptibility measurement.
Includes broad testing across multiple antibiotics via MB04 and MB07 panels.
Automated incubation, detection, analysis, and Windows-based software streamline workflow.
Designed for in-clinic use in veterinary environments.
Reduces dependence on external laboratories for AST.
Fights antimicrobial resistance (AMR) by providing actionable data quickly so veterinarians can prescribe the most effective antibiotics.
Improves animal clinical outcomes by significantly reducing diagnostic delays that can worsen infections.
Simplifies clinic operations by bringing AST capabilities directly into the practice, eliminating costly central lab turnaround times.
Supports antimicrobial stewardship — better antibiotic use helps preserve efficacy and slows the spread of resistance.
MedFluid is a Taiwan-based diagnostics company (founded in 2019) focused on developing microfluidics-based biomedical testing platforms, particularly for rapid diagnostics and precision treatment tools for both human and animal health. The company’s mission is to make advanced diagnostic testing affordable, easy to use, and clinic-friendly, enabling more effective clinical decisions and improving clinical outcomes.
